Yes, of course you adapt, and one of the problems we have in the TPP is that on certain issues it locks us in without the ability to adapt. A perfect example would be on protection for biologics. This, as many of you know, is really the next-generation pharmaceuticals where we are at just the very early stages of these kinds of new technologies—
On May 5th, 2016. See this statement in context.